Oncolytic virus-armed gene therapy may offer new treatment options and improve the prognosis for patients with colon cancer. In this study, we sought to further confirm the antitumor activity of oncolytic virus-armed tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy in xenografts, which derived from the tumors of patients with colon cancer. To this end, we established xenotransplantable tumors from fresh surgical specimens. The histology of these xenografts maintained the features of the original tumors during passaging in nude mice. We next treated these xenografts with adenoviruses carrying TRAIL and the adenovirus E1A gene (Ad/TRAIL-E1) driven by the human telomerase reverse transcriptase promoter. The vector expressing the TRAIL gene (Ad/gTRAIL) or the E1A gene (Ad/GFP-E1) alone was used as control vector. The results demonstrated that Ad/TRAIL-E1 had more significant inhibitory effects on tumor growth than Ad/gTRAIL or Ad/GFP-E1 alone. Furthermore, we did not find any obvious treatment-related toxicity in the mice. Our results indicate that the use of an oncolytic adenoviral vector, in combination with TRAIL gene therapy, is a promising novel approach for cancer therapy.
Introduction
Colorectal cancer is the third most common malignant tumor worldwide. The annual incidence of this disease was 1.02 million in the year 2002. 1 Over the past decade, significant progress has been made in the treatment of localized colorectal cancer because of advances in surgery, radiotherapy and chemotherapy. 2 Nevertheless, the 5-year overall survival rate for patients with colorectal cancer has improved only from 51 to 65% over the last 25 years. 3 Thus, there is an urgent need to develop new therapeutic agents to treat colorectal cancers.
One such anticancer therapeutic agent is tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), also known as Apo-2L, which belongs to the tumor necrosis factor family. 4, 5 Many studies have shown that TRAIL can induce apoptosis in a broad range of cancer cell types, but not in normal cells and tissues, suggesting that it could be a potential therapeutic agent used in the treatment of cancer. [6] [7] [8] However, the clinical application of recombinant TRAIL may be limited by the facts that only large amounts of TRAIL elicit antitumor activity and that a substantial number of tumor cells are resistant to recombinant TRAIL proteins. [9] [10] [11] Recently, virotherapy has been extensively investigated for possible efficacy in cancer therapy. Virotherapy uses oncolytic viruses engineered to selectively replicate within, and thus kill tumor cells. 12, 13 One of the earliest engineered oncolytic viruses used in clinical trials was ONYX-015, which has been used in various stage I, II and III clinical trials for pancreatic, liver, head and neck cancers. In China, H101, a modification of this vector, has been clinically approved for the treatment of several malignancies. 14 However, the efficacy of oncolytic adenovectors as a single agent is limited because they result in inefficient cell lysis and cell death. [15] [16] [17] To overcome the weakness of both TRAIL therapy and virotherapy when used individually, we recently constructed a TRAIL-expressing oncolytic adenoviral vector (Ad/TRAIL-E1), in which the expression of both the TRAIL and E1A genes were under the control of a synthetic promoter consisting of sequences from the human telomerase reverse transcriptase promoter and a minimal cytomegalovirus (CMV) early promoter. Our previous studies showed that Ad/TRAIL-E1 could effectively suppress the growth of a tumor cell linederived xenograft. 18 In this study, we successfully established colon cancer patient-derived xenografts directly from surgical specimens in nude mice, and evaluated the antitumor effect of Ad/TRAIL-E1 in vivo in these xenografts. Our results showed that treatment with Ad/TRAIL-E1 produced the greatest tumor growth inhibition and the highest percentage of apoptotic cells as compared with control adenovectors in patient-derived colon cancer xenografts.
Materials and methods

Animals
We used 6-8-week-old female BALB/c nude mice (Institution of Animal Research, Shanghai, China) as xenograft recipients for human tumor fragments. They were housed under sterile conditions in a pathogen-free environment. The mice were provided with sterile water and food ad libitum, and all manipulations were carried out aseptically inside a laminar flow hood. Animal experiments were carried out in accordance with institutional guidelines for animal care of Zhejiang University.
Patient tumors
Colon tumor tissue specimens were obtained from 21 patients undergoing surgery at the Sir Run Run Shaw Hospital (Hangzhou, China) at the time of surgery after informed written patient consent was obtained. All samples were obtained from primary tumors. To ensure sterility, all tumor samples were incubated for 5 min at room temperature in Povidone-lodine (Mingsheng Pharma, Hangzhou, China) and washed with a solution of 300 mg ml À1 gentamycin (Invitrogen, Carlsbad, CA) three times.
Establishment of tumor xenografts
Tumor tissues were cut into 3-4 mm fragments with a scalpel. After avertin anesthesia, pieces of freshly obtained surgical specimens were implanted subcutaneously (s.c.) into 3-4 nude mice within 2 h after the specimens were collected during surgery. These mice were monitored until their tumors reached 1 cm in diameter, then the tumor was removed and implanted into new mice to produce multiple generations. After the second passage, a mouse with a 1-2-cm tumor was used as a donor to implant tumors into other experimental mice. Mice were assigned randomly to control or treatment groups. At the time points indicated, mice were killed by cervical dislocation, and the tumors were removed by dissection and fixed in neutral-buffered formalin for further study. The morphology of patients' tumor tissues was compared with their corresponding xenografts using paraffin-embedded sections stained with hematoxylin and eosin.
Adenovirus
The human telomerase reverse transcriptase-CMV promoter was created as described previously. 19 Ad/CMV-GFP, Ad/GFP-E1, Ad/gTRAIL and Ad/TRAIL-E1 have been described previously. 18, 20, 21 Ad/TRAIL-E1 is a telomerase-specific replication-competent adenovirus, the expression of both the TRAIL and viral E1A genes is under the control of the human telomerase reverse transcriptase-CMV fusion promoter. Vector amplification, purification, titration and quality tests were performed as previously reported. 22 The viral titer used in this study was determined by the absorbance of the dissociated virus at A 260 nm (1 A 260 nm unit ¼ 10 12 viral particles per ml) and the plaque assay. Particle/infectious unit ratios were usually between 30:1 and 100:1. Thus, the multiplicity of infection of 100 viral particles was equivalent to an multiplicity of infection of 1-3 infectious units. Unless otherwise specified, Ad/CMV-GFP was used as the vector control, and phosphate-buffered saline (PBS) was used as the mock control. Ad/gTRAIL was used as a control of a non-oncolytic adenovirus expressing the TRAIL gene, and Ad/GFP-E1 was used as a control of an oncolytic adenovirus without TRAIL. All of the resulting viral preparations were determined to be free of contamination by wild-type adenovirus or endotoxin.
Treatment protocol
Fragments of human colon tumors were implanted s.c. into nude mice. At 1-2 weeks after the tumor tissue implantation, when the average size of tumors reached 4-5 mm in diameter (a mean volume of 40-50 mm 3 ), the mice were randomized into five treatment groups: PBS, Ad/CMV-GFP, Ad/GFP-E1, Ad/gTRAIL, or Ad/TRAIL-E1 (six mice per group). For each treatment, 100 ml PBS with or without 2.5 Â 10 10 viral particles adenovirus were injected intratumorally with a 27-gauge needle. The treatments were repeated every 3 days for a total of four treatments. Mice were ear-tagged so that data obtained from individual animals could be traced. The tumors were measured every 2 days with calipers for 1 month, and their relative tumor volumes were calculated using the formula: a(b 2 )/2, for which a and b represented the longest and shortest diameters, respectively. The mice were euthanized when their tumors reached 1.5 cm in diameter or became ulcerated. To assess the toxicity of the treatments, we collected blood samples 2 days after the final injection from the tail veins of the mice and we measured the concentrations of serum liver enzymes, the blood cell counts (red cells and white cells), hemoglobin concentrations and platelet levels. At the same time point, one mouse was killed in each group and several organs (liver, lung, kidney and heart) were also removed by dissection, fixed in neutral-buffered formalin, and embedded in paraffin for assessment of histopathological changes. In another set of experiments, 25 mice with tumor 21 835x were randomly assigned to same five treatment groups (n ¼ 5). Each tumor was treated only once, and after 2 days, tumors were removed for performance of the in vivo adenovirus replication assay and terminal deoxyribonucleotide transferase-mediated nick-end labeling assay.
Apoptosis assay
To detect apoptotic cells in tumors, we used the In Situ Cell Death Detection Kit, POD (Roche, Indianapolis, IN). Paraffin sections, 4-mm-thick, of tumor were deparaffinized in xylene and rehydrated in decreasing After sections were rinsed in distilled water, endogenous peroxidase was blocked by incubating the slides in 3% hydrogen peroxide in PBS (pH 7.4) for 5 min. After being washed with PBS, the sections were incubated terminal deoxyribonucleotide transferase in a humidified chamber at 37 1C for 60 min. After being rinsed in PBS, the sections were incubated with horseradish peroxidase in a humidified chamber at 37 1C for 30 min. Peroxidase activity in each section was demonstrated using 3-3 0 -diaminobenzidine (DAB; Roche). Hematoxylin was used as a counterstain. To quantify apoptosis, at least 2000 cells were counted by a pathologist under a microscope in several random fields. The number of apoptotic cells was divided by the total number of cells counted, and the result was expressed as percentage of apoptotic cells. Histological images were captured using a Nikon ECLIPSE 80i microscope (Nikon, Tokyo, Japan) and Nikon NISElements Documentation software.
In vivo adenovirus replication assay
To assess the efficacy of adenovirus replication in vivo, we removed whole tumors from mice 2 days after a singe treatment with various adenoviruses. The tumors were homogenized in 0.5 ml of cold PBS and centrifuged. The viral vector replication rate in the tumor lysate supernatant was determined using the tissue culture infectious dose 50 assay in fresh 293 cells as described previously. 23 
Statistical analysis
The results were expressed as mean±s.d. The GraphPad Prism 5.0 program (GraphPad Software, San Diego, CA) was used for data handling and analysis. Differences among the treatment groups were assessed by one-way analysis of variance and two-way analysis analysis of variance with Bonferroni's post tests. Survival curves were plotted according to the Kaplan-Meier method, and survival fraction across treatment groups was compared using log-rank test analyses. P-value of p0.05 was considered to be a significant difference.
Results
Establishment of xenografts from colon tumor surgical specimens We s.c. implanted a total of 21 surgical specimens derived from human colon tumors into nude mice. Of these 21 specimens, 3 resulted in tumor growth at the site of graft, all of which were maintained by serial transplantation for up to the 10 passages. These patient tumor samples are, henceforth, referred as tumor 16 670, 18 657 and 21 835. Their corresponding xenografts are referred as tumor 16 670x, 18 657x and 21 835x. All xenografts went through an initial phase of tumor regression immediately after transplantation, followed by the reappearance of a palpable tumor and progressive tumor growth. The latency of tumors 16 670x, 18 657x and 21 835x (the delay between engraftment and a tumor size of 100 mm 3 ) were highly variable, with values of 15, 30 and 18 days, respectively. Their doubling times, which were measured during the period of time from which the tumor grew from 250 to 500 mm 3 , were 11, 8 and 5 days, respectively. These parameters were measured between passages three and five, and there were few variations from one passage to another. This heterogeneity in growth rate probably reflects inherent patient-to-patient differences. We also examined the lung, heart, liver and kidneys of mice, when the tumor mass reached the maximum size deemed ethical before killing to search for metastases, but none were found.
The comparison between the histology of the original tumors and their xenografts was performed during both early (first to third) and later passages without any observable modifications. Histological evaluation of these tumors demonstrated that engrafted tumors maintained a remarkable degree of similarity, in terms of the histological features seen, to the original tumors. Ad/TRAIL-E1 suppressed tumor growth and prolonged survival in patient-derived colon cancer xenografts After establishing colon cancer xenografts from patients who had undergone surgery for colorectal cancer in nude mice, we evaluated the antitumor activity of Ad/TRAIL-E1 in three tumor models. In tumor 16 670x models, the group treated with Ad/GFP-E1 and Ad/gTRAIL had moderate inhibitory effect on tumor growth compared with the mock treatment (PBS) or the control vector (Ad/CMV-GFP) alone (Po0.01). Treatment with Ad/ TRAIL-E1 exhibited significant tumor suppression as compared with treatment with Ad/GFP-E1 and Ad/gTRAIL (Po0.05, Figure 2a) . The mean survival times for mice treated with PBS, Ad/CMV-GFP, Ad/GFP-E1, Ad/gTRAIL and Ad/TRAIL-E1 were 40, 44, 51, 48 and 65 days, respectively. Treatment with Ad/gTRAIL did not increase the survival time compared with treatment with PBS or Ad/CMV-GFP (P40.05). Treatment with Ad/GFP-E1 prolonged the survival time compared with treatment with PBS or Ad/CMV-GFP (Po0.05). Moreover, treatment with Ad/TRAIL-E1 further prolonged the survival time compared with treatment with Ad/GFP-E1 and Ad/gTRAIL (Po0.05, Figure 2b ).
In the tumor 18 657x models, treatment with Ad/GFP-E1 and Ad/gTRAIL also had moderate inhibitory effect on tumor growth compared with treatment with PBS or Ad/CMV-GFP (Po0.01). Treatment with Ad/TRAIL-E1 exhibited significant tumor suppression as compared with In addition, the body weight of each mouse was measured before treatment was started and 1 month after the first treatment. No differences in the body weight were found in the tumor 16 670x and 18 657x models. However, in the tumor 21 835x models, treatment with Ad/TRAIL-E1 significantly increased body weight in the mice who received it as compared with mice who received mock treatment, control vector treatment, or treatment with Ad/GFP-E1 (Po0.05) at day 25 ( Figure 3a) . Since doubling times of the tumor 21 835x models were much more faster than other two tumor models, this increase in body weight may have reflected a reduced tumor burden and therefore improved health in these mice.
Treatment-related toxicity
We also tested the toxicity of the treatments in animals that received adenoviral vectors as part of their treatment. For this testing, serum liver enzymes and blood cell counts (red blood cell, white blood cell, hemoglobin and platelets) were collected 2 days after the final injection. Analysis of serum alanine aminotransferase and aspartate aminotransferase levels showed that they were both in the normal range in all treatment groups (Figure 3b ). The result of the analysis of blood cell counts revealed that there were no substantial differences between the groups Treat patient-derived xenografts with Ad/TRAIL-E1 W Zhou et al (data not shown). We also examined the histopathological changes that occurred in the liver, lung, kidney and heart of the mice after these organs were collected. No obvious lesions were found in any of the organs in either treatment group (Figure 3c ).
Analysis of apoptosis induction by Ad/TRAIL-E1
Histopathological examination of hematoxylin and eosinstained tumor tissue sections revealed no obvious inflammation in any mice 2 days after a single injection (Figure 4a ). To assess apoptosis induction in vivo, we performed terminal deoxyribonucleotide transferasemediated dUTP nick-end labeling staining on tumor sections at the same time point in all five groups (Figure 4a ). The degree of apoptosis observed in the tumors treated with Ad/GFP-E1 (6.98%) or Ad/gTRAIL (7.21%) alone was significantly higher than that seen in the tumors of mice in the mock treatment (1.58%) or control vector (Ad/CMV-GFP) treatment (2.21%) groups (Po0.01). The tumors with largest number of apoptotic cells were observed in mice treated with Ad/TRAIL-E1 (15.84%). The rate of apoptosis was also significantly higher in this group than in the mock treatment or control vector (Ad/CMV-GFP) treatment group (Po0.01). Furthermore, the degree of apoptosis observed in the tumors treated with Ad/TRAIL-E1 was significantly higher than that seen in the tumors treated with Ad/GFP-E1 or Ad/gTRAIL (Po0.01) (Figure 4b ). , the lowest dilution the assay could measure) were found in the tumor lysates derived from mice treated with Ad/CMV-GFP or Ad/gTRAIL, demonstrating that oncolytic vectors, but not the E1-defective vectors could replicate in those tumor cells, Treat patient-derived xenografts with Ad/TRAIL-E1 W Zhou et al and the efficiency of Ad/TRAIL-E1 was even better as compared with Ad/GFP-E1.
Discussion
Human tumor xenografts grown in nude mice or severe combined immunodeficiency mice comprise the major model systems used for the development of novel cancer therapeutics in vivo. 24, 25 However, the predictive value of these models has been debated extensively. In the National Cancer Institute drug development program, data on 39 agents that had completed Phase II trials and that had also been evaluated using in vivo tumor models were compared and the investigators found that only 33% of tested xenograft models were predictive of clinical efficacy. 26 However, it should be noted that the National Cancer Institute study used xenografts, which were derived from cell lines that had been cultured for a long period of time in monolayers on plastic dishes and had lost most of their original tumor tissue specificity. Tumor models established from the surgical specimens of human tumors may overcome some of these limitations. It has been demonstrated that xenografts created through the direct engraftment of patient biopsies into animals maintain the cell differentiation, morphology, In this study, we established the colon tumor-derived xenografts directly from surgical specimens of colon cancer patients, thereby avoiding any intermediate cell culturing, which can lead to the development of tumors that do not share the characteristics of the respective original tumor because of the selection and expansion of specific cell clones. Histological comparison of the established xenografts and the original patients' tumors demonstrated that the xenografts were of the same histological type and had the same differentiation as the original tumors, even after several passages (we performed no more than 10 passages in this study). In addition, the implanted tumor tissue still retained most of its normal architecture, including tumor-associated stroma. There is accumulating evidence that the tumor's native stroma and extracellular matrix have critical roles in tumor growth, malignant progression, metastatic spread and pharmacological response. 28, 29 Other groups have previously shown that the drug response of patient tumor xenografts was highly correlated with the clinical outcome of the patients from whom the tumor tissue was derived in colorectal cancers, breast cancers and childhood cancers. 27, 30, 31 Freiburg's group reported previously that the drug response of xenografts derived from patient samples correctly predicted the response in 90% of patients and resistance in 97% of patients. 32 The site of tumor implantation is another important variable. It is well known that s.c. transplanted human tumors rarely develop metastases in nude mice. Some groups established metastatic tumor models through orthotopic implantation. However, orthotopic transplantation is technically difficult and would require expensive and time-consuming imaging techniques. S.c. implantation is relatively easy to assess antitumour effects through the use of callipers to determine tumor volume. Although discussions are ongoing, arguing that the orthotopic transplantation model more closely resembles the situation in the patient, subcutaneous xenografts still remain the standard for cancer drug screening in the pharmaceutical industry.
Currently, most studies investigating the effects of standard chemotherapeutic agents alone or in combination are performed in patient-derived cancer xenografts. 27, 30 Only a few studies have used patient-derived xenograft models to investigate the response to 'targeted' therapeutics. 33, 34 In the present study, we used our patient-derived model system to investigate the efficacy of adenoviral gene therapy. Our results demonstrated that although these patient colon tumors exhibited great heterogeneity in their latency and doubling time in nude mice, the antitumor activity of adenovector could be greatly augmented by integrating using TRAIL gene therapy and oncolytic adenovirotherapy. The tumor inhibition rate of Ad/TRAIL-E1 was 71-87%, which was better than that of Ad/gTRAIL (45-57%) or Ad/GFP-E1 (51-64%). We also observed that the tumor inhibition rate of the chemotherapeutic agents 5-fluorouracil (5-FU) in our patient-derived tumor xenografts was about 40% (data not shown). This may be important clinically because 5-FU-based adjuvant chemotherapy has been shown to be efficacious in reducing mortality in patients with lymph node-positive colon cancer and has become the standard of care for these patients. 2 Moreover, it should be noted that treatment with Ad/TRAIL-E1 led not only to the greatest tumor suppression and regression, but also the complete elimination of some tumors, suggesting Ad/TRAIL-E1 might be a potent anti-tumor agent as compared with Ad/gTRAIL or Ad/GFP-E1.
In this study, we evaluated potential treatment-related toxicity of adenovirus vectors in nude mice model using local injection. We found no substantial differences among the treatment groups, indicating low toxicity of Ad/TRAIL-E1. However, the potential toxicity of Ad/TRAIL-E1 using systemic administration could be higher and further study is needed. Actually, we are currently investigating the antitumor effects of Ad/TRAIL-E1 using intraperitoneal injection in peritoneal disseminated xenografts and found no detectable toxicity (unpublished data).
The in vivo replication data confirmed that Ad/TRAIL-E1 and Ad/GFP-E1 treatment led to the efficient release of vector progeny in the tumor tissue of our patientderived xenografts. Interestingly, the final yield of infectious viral units in tumors treated with Ad/TRAIL-E1 was much higher than in those treated with Ad/GFP-E1. The cause of this difference between Ad/TRAIL-E1 and Ad/GFP-E1 in terms of generating viral progeny is not yet clear. However, it has been shown that induction of viral apoptosis late in viral replication can accelerate viral spread through the dissemination of de novo produced particles through endocytosis of apoptotic bodies. 35 Data from a growing number of clinical studies have suggested that the dissemination of viruses in tumors is incomplete and contributes to the failure of virotherapy. [36] [37] [38] The most common outcome of any virotherapy in previous studies was the escape of tumor cells and subsequent regrowth of the tumor. An obvious way of enhancing the cancer-killing potency of an oncolytic virus is to engineer it to produce a protein that is toxic to the cell, either directly or by inducing sensitization to cell death. 39 For example, expression of Fas-ligand or p53 by adenoviral vectors has been shown to enhance their oncolytic effect both in vitro and in vivo without increasing toxicity to normal cells. 40 In this study, we found that expression of the TRAIL gene by oncolytic adenoviruses resulted in enhanced apoptosis and viral replication in patientderived xenograft models. The increased therapeutic effect that we observed might result from the increased expression of the therapeutic gene resulting from the increased number of copies produced by E1A-controlled replication and the increased viral release caused by TRAIL-induced apoptosis. E1A also enhances TRAILinduced caspase-8, caspase-9 and Apaf-1 activation, suggesting that activation of the mitochondrial-dependent apoptotic pathway is the main pathway by which E1A sensitization of cancer cells leads to TRAIL-induced apoptosis. 41 Therefore, coordinated triggering of apoptosis
Treat patient-derived xenografts with Ad/TRAIL-E1 W Zhou et al by both the TRAIL and E1A genes in the oncolytic vector may be another mechanism that can be used to enhance the efficacy of oncolytic virotherapy. In summary, we established human cancer xenografts from human colon tumor surgical specimens whose histology revealed a high concordance with their respective original human counterparts. Our results demonstrated that with the combined advantages provided by TRAIL gene and oncolytic virotherapy, Ad/TRAIL-E1 treatment improved both tumor suppression and survival in all established models.
